Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Up 71.2% in March

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totaling 39,674 shares, an increase of 71.2% from the March 15th total of 23,175 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 168,599 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Craig Hallum reaffirmed a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. BTIG Research reduced their price objective on shares of Xtant Medical from $1.50 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $1.00.

Xtant Medical Price Performance

Shares of XTNT stock remained flat at $0.51 during trading hours on Wednesday. The stock had a trading volume of 11,308 shares, compared to its average volume of 164,931. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.65 and a quick ratio of 1.63. The company has a market capitalization of $71.44 million, a price-to-earnings ratio of 17.01 and a beta of -0.16. The stock has a fifty day moving average price of $0.57 and a 200 day moving average price of $0.66. Xtant Medical has a 1-year low of $0.39 and a 1-year high of $0.95.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its earnings results on Tuesday, March 31st. The medical device company reported $0.03 EPS for the quarter. The business had revenue of $32.36 million for the quarter, compared to analysts’ expectations of $30.75 million. Xtant Medical had a net margin of 3.71% and a return on equity of 10.27%.

Institutional Investors Weigh In On Xtant Medical

Hedge funds have recently made changes to their positions in the business. Wiregrass Investment Management LLC acquired a new position in Xtant Medical in the 4th quarter valued at about $81,000. Renaissance Technologies LLC lifted its position in Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after acquiring an additional 205,945 shares during the period. Tradition Wealth Management LLC purchased a new position in shares of Xtant Medical in the 4th quarter valued at approximately $79,000. Hillsdale Investment Management Inc. acquired a new position in shares of Xtant Medical in the fourth quarter valued at approximately $284,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Xtant Medical in the fourth quarter valued at approximately $220,000. Institutional investors and hedge funds own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.